Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Hirschfeld, R. M.A. Articles by Grossman, F. Search for Related Content PubMed Citation Articles by Hirschfeld, R. M.A. Articles by Grossman, F. Bipolar Disorder Atypical Neuroleptics

Rapid Antimanic Effect of Risperidone Monotherapy: A 3-Week Multicenter, Double-Blind, Placebo-Controlled Trial

OBJECTIVE: This study evaluated the efficacy and safety of risperidone monotherapy in the treatment of acute bipolar mania. METHOD: Patients with DSM-IV bipolar I disorder experiencing an acute manic episode (baseline Young Mania Rating Scale score 20) were randomly assigned to 3 weeks of treatment with risperidone (flexible dose: 1–6 mg/day) or placebo. The primary efficacy measure was the mean baseline-to-endpoint change in total score on the Young Mania Rating Scale. Secondary efficacy measures included the Clinical Global Impression (CGI) severity rating and scores on the Montgomery-Åsberg Depression Rating Scale, Positive and Negative Syndrome Scale, and Global Assessment Scale (GAS). Safety assessments consisted of monitoring adverse events, vital signs, electrocardiogram and laboratory results, and scores on the Extrapyramidal Symptom Rating Scale. RESULTS: Subjects (N=259) received treatment with either risperidone (N=134) or placebo (N=125). The mean modal dose of risperidone was 4.1 mg/day. Improvement in mean Young Mania Rating Scale total score (adjusted for covariates) was significantly greater in the risperidone than in the placebo group at endpoint (mean change=–10.6 [SD=9.5] versus –4.8 [SD=9.5], respectively), with significant between-group differences seen as early as 3 days after start of treatment (change with risperidone: mean=–6.8 [SD=5.8]; change with placebo: mean=–4.0 [SD=5.8]) and continuing throughout all time points. Improvements in CGI severity ratings and scores on the Montgomery-Åsberg Depression Rating Scale, Positive and Negative Syndrome Scale, and GAS were also significantly greater among patients receiving risperidone than those given placebo. The most common adverse event reported among risperidone patients was somnolence. While Extrapyramidal Symptom Rating Scale scores were significantly greater in patients receiving risperidone, mean total and subscale scores were low. CONCLUSIONS: Risperidone monotherapy was significantly more efficacious than placebo in the treatment of acute mania and demonstrated a rapid onset of action. Risperidone was well tolerated by patients in this study.

This article has been cited by other articles:

				J. Cookson Atypical antipsychotics in bipolar disorder: the treatment of mania Advan. Psychiatr. Treat., September 1, 2008; 14(5): 330 - 338. [Abstract] [Full Text] [PDF]

				A. Yildiz, S. Guleryuz, D. P. Ankerst, D. Ongur, and P. F. Renshaw Protein Kinase C Inhibition in the Treatment of Mania: A Double-blind, Placebo-Controlled Trial of Tamoxifen Arch Gen Psychiatry, March 1, 2008; 65(3): 255 - 263. [Abstract] [Full Text] [PDF]

				J. J. Guo, P. E. Keck, H. Li, and N. C. Patel Treatment Costs Related to Bipolar Disorder and Comorbid Conditions Among Medicaid Patients With Bipolar Disorder Psychiatr Serv, August 1, 2007; 58(8): 1073 - 1078. [Abstract] [Full Text] [PDF]

				H. Scherk, F. G. Pajonk, and S. Leucht Second-Generation Antipsychotic Agents in the Treatment of Acute Mania: A Systematic Review and Meta-analysis of Randomized Controlled Trials Arch Gen Psychiatry, April 1, 2007; 64(4): 442 - 455. [Abstract] [Full Text] [PDF]

				G. S. Sachs Bipolar Disorder Clinical Synthesis: Where Does the Evidence Lead? Focus, January 1, 2007; 5(1): 3 - 13. [Abstract] [Full Text] [PDF]

				R. M. A. Hirschfeld Guideline Watch (November 2005): Practice Guideline for the Treatment of Patients with Bipolar Disorder, 2nd Edition Focus, January 1, 2007; 5(1): 34 - 39. [Abstract] [Full Text] [PDF]

				Bibliography BIPOLAR DISORDER Focus, January 1, 2007; 5(1): 40 - 43. [Full Text] [PDF]

				S. Khanna, E. Vieta, B. Lyons, F. Grossman, M. Kramer, and M. Eerdekens Authors' reply The British Journal of Psychiatry, May 1, 2006; 188(5): 490 - 491. [Full Text] [PDF]

				P. Tyrer Editor's reply The British Journal of Psychiatry, May 1, 2006; 188(5): 491 - 492. [Full Text] [PDF]

				A. A. Nierenberg, M. J. Ostacher, J. R. Calabrese, T. A. Ketter, L. B. Marangell, D. J. Miklowitz, S. Miyahara, M. S. Bauer, M. E. Thase, S. R. Wisniewski, et al. Treatment-Resistant Bipolar Depression: A STEP-BD Equipoise Randomized Effectiveness Trial of Antidepressant Augmentation With Lamotrigine, Inositol, or Risperidone Am J Psychiatry, February 1, 2006; 163(2): 210 - 216. [Abstract] [Full Text] [PDF]

				M. Tohen, J. R. Calabrese, G. S. Sachs, M. D. Banov, H. C. Detke, R. Risser, R. W. Baker, J. C.-Y. Chou, and C. L. Bowden Randomized, Placebo-Controlled Trial of Olanzapine as Maintenance Therapy in Patients With Bipolar I Disorder Responding to Acute Treatment With Olanzapine Am J Psychiatry, February 1, 2006; 163(2): 247 - 256. [Abstract] [Full Text] [PDF]

				Drug treatments for bipolar disorder: 1 - Acute manic or depressive DTB, April 1, 2005; 43(4): 28 - 32. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2004 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us